The Gross Margin of Ionis Pharmaceuticals, Inc. (IONS) is
98.31%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
98.31%
|
| 2024-12-31 |
98.41%
|
| 2023-12-31 |
98.84%
|
| 2022-12-31 |
97.60%
|
| 2021-12-31 |
98.67%
|
| 2020-12-31 |
98.37%
|
| 2019-12-31 |
99.61%
|
| 2018-12-31 |
99.70%
|
| 2017-12-31 |
100.00%
|
| 2016-12-31 |
100.00%
|
| Ticker |
Name |
Value |
|
FATE
|
Fate Therapeutics Inc
|
7775.20%
|
|
RVMD
|
Revolution Medicines, Inc.
|
7775.20%
|
|
ASND
|
Ascendis Pharma A/S
|
86.82%
|
|
FGEN
|
FibroGen Inc
|
47.47%
|
|
HALO
|
Halozyme Therapeutics, Inc.
|
83.62%
|
|
KOD
|
Kodiak Sciences Inc.
|
7775.20%
|
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
89.81%
|
|
SRPT
|
Sarepta Therapeutics, Inc.
|
69.33%
|
|
LGND
|
Ligand Pharmaceuticals Incorporated
|
74.78%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
7775.20%
|
|
SANA
|
Sana Biotechnology, Inc.
|
7775.20%
|
|
BPMC
|
Blueprint Medicines Corp
|
96.04%
|
|
TGTX
|
TG Therapeutics, Inc.
|
83.66%
|
|
ALLO
|
Allogene Therapeutics, Inc.
|
7775.20%
|
|
IOVA
|
Iovance Biotherapeutics Inc
|
34.28%
|
|
SWTX
|
SpringWorks Therapeutics, Inc.
|
93.45%
|
|
UTHR
|
United Therapeutics Corporation
|
87.92%
|
|
XLRN
|
Acceleron Pharma Inc
|
100.00%
|
|
ALKS
|
Alkermes Plc
|
86.69%
|
|
CCXI
|
Churchill Capital Corp XI
|
99.06%
|
|
EBS
|
Emergent BioSolutions Inc.
|
56.09%
|
|
LEGN
|
Legend Biotech Corporation
|
60.34%
|
|
ARNA
|
Arena Pharmaceuticals Inc
|
78.92%
|
|
BHVN
|
Biohaven Ltd.
|
72.18%
|
|
FOLD
|
Amicus Therapeutics Inc
|
88.50%
|
|
RLAY
|
Relay Therapeutics, Inc.
|
7775.20%
|